S&P Futures
3,855.00+10.00(+0.26%)Dow Futures
31,143.00+47.00(+0.15%)Nasdaq Futures
13,368.00+73.75(+0.55%)
Aethlon Medical, Inc. (AEMD)
2.6700 0.00 (0.00%)
After hours: 7:41PM EST
Chart Events
Performance Outlook
| Previous Close | 2.5500 |
| Open | 2.6000 |
| Bid | 2.6600 x 1100 |
| Ask | 2.7300 x 1300 |
| Day's Range | 2.5696 - 2.7700 |
| 52 Week Range | 1.1800 - 4.3400 |
| Volume | 568,926 |
| Avg. Volume | 1,983,158 |
| Market Cap | 32.276M |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7060 |
| Earnings Date | Feb 08, 2021 - Feb 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- PR Newswire
Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer
Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced the expansion of its executive team with two key appointments: Guy Cipriani as Senior Vice President and Chief Business Officer, and Steven LaRosa, M.D., as Chief Medical Officer. In his new role, Mr. Cipriani will oversee business development and partnerships, while also contributing to fundraising and corporate development. Dr. LaRosa will be responsible for the clinical development of Aethlon's Hemopurifier®, including leading clinical operations and regulatory strategy.
- PR Newswire
Aethlon Medical to Present at the H.C. Wainwright BioConnect 2021 Conference
Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held Jan. 11-14, 2021.
- PR Newswire
Aethlon Medical Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer
Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the first patient has been treated in the Company's first-in-human Early Feasibility Study (EFS) evaluating the HEMOPURIFIER® in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The study is enrolling patients at UPMC Hillman Cancer Center in Pittsburgh, PA. (Hemopurifier Plus Pembrolizumab in Head and Neck Cancer - Full Text View - ClinicalTrials.gov).
